Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial (2023)

First Author: Freeman S
Attributed to:  Biology and Treatment of Human Myeloid Cancers funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood.2023020630

Publication URI: http://dx.doi.org/10.1182/blood.2023020630

Type: Journal Article/Review

Parent Publication: Blood

Issue: 20